A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer

Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Study ID
NCT07654400
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Extensive-stage Small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BL-M14D1 — DRUG
    Administration by intravenous infusion for a cycle of 3 weeks.
  • Atezolizumab — DRUG
    Administration by intravenous infusion for a cycle of 3 weeks.

Study Details

This Phase II study is a clinical study exploring the efficacy and safety of BL-M14D1 in combination with Atezolizumab in patients with extensive-stage small cell lung cancer.

Key Dates

First listed
Jun 17, 2026
Start date
Jul 9, 2026
Status verified
Aug 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BL-M14D1+ Atezolizumab
    Participants receive BL-M14D1+ Atezolizumab for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Up to approximately 12 months ]

Central Contacts

Related Studies